职称：教授、博士生导师

邮箱：icmwl@sdu.edu.cn

研究领域：药物晶型主动设计与调控、药物晶体结构与性质研究；有机及药物晶体成核以及生长动力学在线观察

个人简历

王蕾，山东大学晶体材料研究院教授，博士研究生导师，主要研究方向药物晶型、共晶主动设计与调控、药物晶体结构与性质研究、有机及药物晶体成核以及生长动力学在线观察等。针对我国对固态药物晶型研究不足的问题，开发药物新晶型或共晶，进行晶型筛选新方法的探索，研究晶型或共晶结构-性质关系，获得具有自主知识产权的固体药物形式。利用原位原子力显微镜，进行药物晶体的成核、生长路径研究，实现晶型的主动调控。

学习与工作经历

山东大学，晶体材料研究所，博士生导师，教授

2006-10至2008-01，新加坡国立大学，物理系，博士后

2016-11至2017-11，美国西北太平洋国家实验室，材料组，访问学者

代表性论文

1.Efficient Screening of Pharmaceutical Cocrystals by Microspacing In-Air Sublimation Huimin Li,Lei Wang*, Xutang Tao* et. al,J. Am. Chem. Soc., 2024, 146, 11592-11598

2.De novo design of self-assembling helical protein filaments，Hao Shen#, Jorge A. Fallas#, Eric Lynch#, William Sheffler, Bradley Parry, Nicholas Jannetty, Justin Decarreau, Michael Wagenbach, Juan Jesus Vicente, Jiajun Chen,Lei Wang,Quinton Dowling, Gustav Oberdorfer, Lance Stewart, Linda Wordeman, James De Yoreo, Christine Jacobs-Wagner, Justin Kollman, David Baker*（2024诺贝尔化学奖获得者），Science，2018, 362, 705–709

3.The new cocrystal of molnupiravir-caprolactam discovered by melt crystallization with improved tableting properties Peizhuo Han,Lei Wang*, Huimin Li,Changlin Yao*,Yaqian Qu, Xu Zhang, Hanlin Zhao, Yaqi Ren, Bozhang Li, Xutang Tao,Int. J. Pharm, 2025, 677, 125661

4.Inhibition Efficiency of Cholesterol Monohydrate Crystallization byLinoleic Acid and Ethyl Linoleate Yaqian Qu,Lei Wang,*Huimin Li, Hanlin Zhao, Changlin Yao, Guanying Xie, Shuhong Song,Peizhuo Han, Hongshuai Wang, and Xutang Tao*,Cryst. Growth Des.2025, 25, 1923-1931

5.Polyethylene Glycol-Assisted Melt Crystallization of Two New Piroxicam Polymorphs Revealed by 3D Electron Diffraction Jiaoyan Xu, Changlin Yao,* Shufang Zhang, Xiaodong Zou, Yue Gui,Lei Wang,*and Hongyi Xu*，Cryst. Growth Des.2024, 24, 7298−7305

6.Polymorphs and Solvates of Molnupiravir: Crystal Structures and Solid Forms Transformation Analysis, Peizhuo Han,Lei Wang*, Xutang Tao*,Cryst. Grow. Des,2024, 24，4758-4769

7.Surface Accelerates Crystal Nucleation: The Case of Molnupiravir Kangning Sun^#, Peizhuo Han^#, Changlin Yao,* Yaning Zhao, Chuanchi Zhang, Yao Zhang,*Jingke Jiang, andLei Wang*,Cryst. Growth Des.2024, 24, 6413-6420

8.Solvates and Polymorphs of Baloxavir Marboxil: Crystal Structure and Phase Transformation Study, Hongshuai Wang,Lei Wang*,Guanying Xie, Changlin Yao, Shuhong Song, Huimin Li, Yaqian Qu, Peizhuo Han, Zeliang Gao, and Xutang Tao*,Cryst. Growth Des.2024, 24, 3399-3409

9.基于原位原子力显微镜的巴洛沙韦酯单晶溶解机制研究，王洪帅，王 蕾*，宋舒虹，陶绪堂*，人工晶体学报，2024, 53, 147-155

10.Solvates and Polymorphs of Baloxavir Marboxil: Crystal Structure and Phase Transformation Study,Hongshuai Wang,Lei Wang*, Xutang Tao*,Cryst. Grow. Des,2024, 24, 3399-3409

11.Classical Spiral Growth Mechanism of Azilsartan Form I Revealed byIn SituAtomic Force Microscopy,Shuhong Song,Lei Wang*, Yaqian Qu, Huimin Li, Hongshuai Wang, Peizhuo Han, Zeliang Gao, and Xutang Tao*,Cryst. Grow. Des,2024, 24, 1319-1327

12.Cocrystals of Favipiravir: Improved Physicochemical Properties and Solution Stability Study, Huimin Li,Lei Wang*,Guanying Xie, Changlin Yao, Shuhong Song, Yaqian Qu, Peizhuo Han, Hongshuai Wang, Yanyan Sun, Huachang Wu, and Xutang Tao*,Cryst. Grow. Des,2023, 23, 8656-8669

13.Different Dissolution Molecular Pathways of Azilsartan Crystals with Different Forms Revealed by In Situ Atomic Force Microscopy, Shuhong Song,Lei Wang*, Guanying Xie, Yaqian Qu, Huimin Li, Hongshuai Wang, Peizhuo Han, and Xutang Tao*,J. Phys. Chem. Lett.,2023, 14, 36, 8191-8198

14.Recent Advances in Polymorph Discovery Methods of Organic Crystals, Changlin Yao, Shufang Zhang*,Lei Wang*, Xutang Tao*,Cryst. Grow. Des,2023, 23, 637-654

15.Novel Formulations of Antiviral Drug Favipiravir: Improving Permeability and Tabletability. Xinyuan Wang,Lei Wang,*Xutang Tao * et al，Cryst. Grow. Des，2021, 21, 3807-3817

16.Size-dependent Solution Mediated Phase Transformation of Piroxicam Monohydrate Particles, Changlin Yao,Lei Wang*, Xinyuan Wang and Xutang Tao*,CrystEngComm,2021, 23, 2928-2932

17.宋舒虹，姚昌林，王蕾*，陶绪堂*，曲亚倩，药物结晶中的经典与非经典结晶路径，人工晶体学报，2021，50，118-133

18.Crystallization of Sulfathiazole in Gel: Polymorph Selectivity and Cross-Nucleation, Shuang Song,Lei Wang,*Changlin Yao, Zhen Wang, Guanying Xie, and Xutang Tao*,Cryst. Growth. Des.2020, 20, 9-16

19.Polymorphism of Piroxicam: New Polymorphs by Melt Crystallization and Crystal Structure Prediction, Changlin. Yao,Lei Wang*, Yu Lian*, et alCryst. Grow. Des,2020, 20, 7874-7881

20.Tuning the Solution-Mediated Concomitant Phase Transformation Outcome of the Piroxicam Monohydrate by Two Hydroxyl Containing Additives: Hydroxypropyl Cellulose and H2O，Changlin Yao, Yifan Li,Lei Wang,*Shuang Song, Bo Li, Yang Liu, and Xutang Tao*,Cryst. Growth Des.2019, 19, 583-590

21.Low-Dimensional Hybrid Lead Iodide Perovskites Single Crystals via Bifunctional Amino Acid Cross-Linkage: Structural Diversity and Properties Controllability, Guanying Xie,Lei Wang*, Peizhou Li, Shuang Song, Zhen Wang, Xinyuan Wang, and Xutang Tao*,ACS Appl. Mater. Interfaces,2021, 13, 3325-3335

22.Thermochromism Perovskite (COOH(CH2)3NH3)2PbI4 Crystals: Single-Crystal to Single-Crystal Phase Transition and Excitation-Wavelength-Dependent Emission Wavelength-Dependent Emission，Guanying Xie,Lei Wang,*Dianxing Ju, Changlin Yao, Xinyuan Wang, Shuhong Song, Yaqian Qu, Huimin Li, and Xutang Tao*，J. Phys. Chem. Lett.2022, 13, 214−221

专著

Shuhong Song,Lei Wang*, Changlin Yao, Yaqian Qu, and Xutang Tao*, Insights into the Classical and Nonclassical Crystallization pathway in Pharmaceutical Science, in Crystallization via Nonclassical Pathways Volume 2: Aggregation, Biomineralization, Imaging & Application,American Chemical Society, 2021

科研项目

1.国家自然科学基金，面上项目，微距升华法制备莫诺拉韦共晶研究，2025-01至2028-12，48万，主持

2.山东省自然科学基金，重大基础研究项目，抗新冠病毒候选药物法匹拉韦共晶研究，2022-01至2024-12，100万，第2位

3.国家自然科学基金委员会, 面上项目, 新型有机-无机复合钙钛矿结构晶体生长及其性能研究, 2018-01至2021-12，60万元, 主持

4.山东省自然科学基金面上项目，ZR2015EM029，喜树碱类药物多晶型及界面诱导成核研究，2015-01至2017-12，17万，主持

5.山东省科技发展计划，2014GSF118057，喜树碱类抗癌药物的多晶型技术研究与应用，2015-01至2016-12，10万，主持

6.国家自然科学基金青年项目，51003054，聚集态荧光增强有机发光微纳米晶及其作为免疫荧光标记材料的研究，2011-01至2013-12，20万元，主持

发明专利

1.王蕾，李慧敏，陶绪堂，宋舒虹，曲亚倩，一种法匹拉韦水合物晶体及其制备方法和应用，申请号CN202311017916.3；

2.王蕾，李慧敏，陶绪堂，谢冠英，宋舒虹，曲亚倩，一种法匹拉韦多组分药物及其制备方法和应用,2024-01-05, 中国,ZL202210164509.4，授权

3.王蕾; 李慧敏; 陶绪堂; 宋舒虹; 曲亚倩 ;一种法匹拉韦-水杨酰胺共晶及其制备方法和应用，2024-04-19, ZL 202310208825.1,授权

4.王蕾; 王新园; 陶绪堂; 谢冠英; 宋舒虹 ; 一种法匹拉韦药物共晶及其制备方法和应用, 2021-10-15, 中国, ZL 202011440615.8，授权

5.王蕾; 王新园; 陶绪堂; 谢冠英; 宋舒虹 ; 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用, 2021-10-15, 中国, ZL 202110956161.8，授权

6.王蕾; 王新园; 陶绪堂; 谢冠英; 宋舒虹 ; 硝苯地平与瑞舒伐他汀钙共无定形药物及其制备方法和应用, 2022-01-11, 中国, ZL 202010750686.1授权

7.王蕾; 仵泽鑫; 陶绪堂; 姚昌林; 宋双 ; 一种无定型的替米沙坦-戊二酸共晶及其制备方法和应用,2019-6-21, 中国, ZL 201611190344.9授权

8.王蕾; 仵泽鑫; 陶绪堂; 姚昌林; 宋双 ; 一种无定型的替米沙坦-庚二酸共晶及其制备方法和应用,2019-6-21, 中国, ZL 201611190342.X授权

9.王蕾; 房兰; 陶绪堂; 仵泽鑫 ; 7-乙基-10-羟基喜树碱晶型及其制备方法与应用, 2016-6-15, 中国, ZL 201510038935.3授权

10.王蕾; 房兰; 陶绪堂; 仵泽鑫 ; 一种7-乙基-10-羟基喜树碱新晶型及其制备方法, 2016-3-30, 中国, ZL CN201510036391.7授权